Malvern Panalytical recognised for role in COVID-19 vaccine development

Published: 4-Jun-2021

His Royal Highness The Earl of Wessex visited the company’s Malvern, Worcestershire, headquarters

Malvern Panalytical, an analytical systems manufacturer and contract services provider, welcomed His Royal Highness The Earl of Wessex to its Malvern, Worcestershire, headquarters. The company was selected for the Royal visit among a small number of other Worcestershire businesses, because of its scientific and technical contribution to the development of medicines and vaccines to treat and prevent COVID-19.

Andrew Heath, Chief Executive, Spectris plc, said: “It has been our pleasure to welcome Prince Edward to our Malvern development and manufacturing facility today and to explain how Malvern Panalytical’s people, products and services are assisting the global effort to fight COVID-19. We are immensely proud of the role the team here is playing in applying its technical and scientific expertise to help alleviate this humanitarian crisis.”

His Royal Highness was introduced to the company’s employees from across the business during his walk through the facility, learning about the roles they play in the development of technologies and services. Also on display were a number of the scientific instruments used by pharmaceutical customers in developing and manufacturing drugs and vaccines.

Malvern Panalytical provided analytical instruments and support to SARS-CoV-2 vaccine labs across the globe.

Mark Fleiner, President, Malvern Panalytical, said: “Throughout 2020 and 2021, we have witnessed our analytical systems and services make a real contribution to the development of protein antigen and mRNA-based COVID-19 vaccines, as well as to the development of antiviral drugs. Malvern Panalytical provides the instruments and expertise to support robust and rapid vaccine development and assist pharmaceutical organisations in assuring the quality of vaccines and other treatments.”

You may also like